Drug targeting strategies for the treatment of inflammatory bowel disease: A mechanistic update

Arik Dahan, Gordon L. Amidon, Ellen M. Zimmermann

    Research output: Contribution to journalReview articlepeer-review

    43 Scopus citations


    The therapeutic management of inflammatory bowel disease (IBD) represents the perfect scenario for drug targeting to the site(s) of action. While existing formulation-based targeting strategies include rectal dosage forms and oral systems that target the colon by pH-, time-, microflora-and pressure-triggered drug release, novel approaches for site-specific delivery in IBD therapy will target the inflamed intestine per se rather than intestinal region. The purpose of this article is to present a mechanistic update on the strategies employed to achieve minimal systemic exposure accompanied by maximal drug levels in the inflamed intestinal tissue. The introduction of biological agents, micro/nanoparticulate carriers including liposomes, transgenic bacteria, and gene therapy opportunities are discussed, as well as the challenges remaining to be achieved in the targeted treatment of IBD.

    Original languageEnglish
    Pages (from-to)543-550
    Number of pages8
    JournalExpert Review of Clinical Immunology
    Issue number4
    StatePublished - 1 Jul 2010


    • Crohns disease
    • biological therapy
    • drug delivery/targeting
    • gene therapy/delivery
    • inflammatory bowel disease
    • microcarriers
    • molecular biopharmaceutics
    • nanocarriers
    • transgenic bacteria
    • ulcerative colitis

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Immunology


    Dive into the research topics of 'Drug targeting strategies for the treatment of inflammatory bowel disease: A mechanistic update'. Together they form a unique fingerprint.

    Cite this